Cytokinetics Inc
CYTK
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.55B
Close$
$-13.33
117.4% downside
Current Fair Value
117.4% downsideOvervalued by 117.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.55 Billion |
|---|---|
| Enterprise Value | $10.57 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.54 |
| Beta | 0.38 |
| Outstanding Shares | 132,086,000 |
Return
| Return on Equity | 515.31% |
|---|---|
| Return on Assets | -46.45% |
| Return on Invested Capital | -48.69% |
Valuation & Multiples
| P/E Ratio | -10.65 |
|---|---|
| PEG | -22.22 |
| Price to Sales | - |
| Price to Book Ratio | -38.38 |
| Enterprise Value to Revenue | 148.93 |
| Enterprise Value to EBIT | -12.45 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | -7.33 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-1.63
Average shareholder expectationRevenue Estimate
$17.59 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-1.47
Average shareholder expectationRevenue Estimate
$36.80 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 39.68% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.20%▼ 116.52% |
|---|---|
| Total Invested | $336.33M▼ 96.51% |
| Investors Holding | 115▼ 377.00% |
ESG Score
No data
About Cytokinetics Inc
CEO: Robert Blum